Jump Financial’s Belite Bio BLTE Stock Holding History

Jump Financial’s Portfolio BLTE Stock Details BLTE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-5,200	Closed	-$238K	–	1908
2023 Q4	$238K	Buy	+5,200	New	+$200K	0.01%	1469

Other funds holding BLTE

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

CSS

Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return

VEA

Virtus ETF Advisers New York $261M AUM 78.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Jump Financial's BLTE Position: Q1 2024 in Review

Jump Financial sold out of Belite Bio (BLTE) in Q1 2024, closing a stake of 5,200 shares — an estimated $238K sold.

Jump Financial first reported a position in BLTE in Q4 2023 and held it in 1 quarter. The position peaked at $238K in Q4 2023. 11 funds tracked by Wall St. Rank hold BLTE as of Q1 2024.

Jump Financial reported no remaining Belite Bio position as of Q1 2024 after selling out during the quarter.
Jump Financial sold 5,200 Belite Bio shares in Q1 2024, an estimated $238K.
Jump Financial first reported a position in Belite Bio in Q4 2023 and held it in 1 quarter.
Jump Financial's Belite Bio position peaked at $238K in Q4 2023.
11 funds tracked by Wall St. Rank held Belite Bio as of Q1 2024.

Based on Jump Financial's 13F filing for Q1 2024, filed 13 May 2024.